Current Headlines

  1. Marken The Preferred Partner To Fight Zika Virus
    2/8/2016

    Marken announced recently they are working with key pharma partners in the race to find a vaccine and treatment for the Zika virus, declared as a public health emergency by the World Health Organization (WHO) earlier this week.

  2. Ametek Announces Two Acquisitions
    2/5/2016

    Brookfield Engineering Broadens AMETEK’s Laboratory Instrumentation Platform ESP/SurgeX Expands AMETEK’s Power Protection Platform

  3. Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars Education Initiative
    2/4/2016

    The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States – issued the following statement about the Biosimilars hearing before the House Energy and Commerce, Subcommittee on Health and the launch of a new biosimilars education initiative.

  4. Beike Biotechnology To Supply 11 Hospitals With Cell Therapy
    2/4/2016

    Beike Biotechnology, the Shenzhen local government, and various medical institutions attended a ceremony in late 2015 to mark their successful combined efforts to provide integrative, personalized cell therapy in 2016.

  5. Phase 3 Study Of BLINCYTO Met Primary Endpoint Of Increased Survival
    2/4/2016

    Amgen (NASDAQ: AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study.

  6. Amgen Announces Positive Results From Phase 3 GAUSS-3 Trial Of Repatha
    2/4/2016

    Amgen (NASDAQ: AMGN) today announced that the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints: mean percent reductions from baseline in low-density lipoprotein cholesterol (LDL-C) at weeks 22 and 24, and the percent reduction from baseline in LDL-C at week 24.

  7. FDA Acknowledges Receipt Of Resubmission Of Shire's New Drug App
    2/4/2016

    Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the New Drug Application (NDA) for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults.

  8. Invetech And Celyad To Collaborate On C-Cure Production
    2/3/2016

    Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Celyad SA, (CYAD.BR) ("Celyad"), a biopharmaceutical company focused on identification and development of specialized cell-based therapies with product candidates in oncology and cardiology, today announced that they have entered into an agreement under which Invetech will develop and supply manufacturing systems to support production needs for C-Cure®, Celyad's most advanced product candidate based on the cardiopoiesis technology platform.

  9. Experts To Meet In Boston To Discuss Biggest Challenges In The Analytical And Clinical Phases Of Biosimilar Drug Development
    2/3/2016

    IQPC has made several recent additions to the speaking faculty of the Biosimilars Clinical Studies & Analytical Similarity Summit.

  10. Morphotek Announces Collaboration With Mayo Clinic On Phase II Trial
    2/3/2016

    Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the Department of Immunology and Edith A. Perez, M.D. in the Department of Hematology and Oncology at Mayo Clinic in Jacksonville, Florida in a clinical study in patients with folate receptor alpha (FRA) positive, triple-negative breast cancer (TNBC).